AT500379A3 - Tau-proteine - Google Patents
Tau-proteine Download PDFInfo
- Publication number
- AT500379A3 AT500379A3 AT0017501A AT1752001A AT500379A3 AT 500379 A3 AT500379 A3 AT 500379A3 AT 0017501 A AT0017501 A AT 0017501A AT 1752001 A AT1752001 A AT 1752001A AT 500379 A3 AT500379 A3 AT 500379A3
- Authority
- AT
- Austria
- Prior art keywords
- tau
- tau proteins
- normal
- proteins
- conformationally different
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0017501A AT500379B8 (de) | 2001-02-02 | 2001-02-02 | Tau-proteine |
CNB028053133A CN100503638C (zh) | 2001-02-02 | 2002-01-29 | tau蛋白 |
RU2003126594/13A RU2299889C2 (ru) | 2001-02-02 | 2002-01-29 | Конформационно аномальные формы белков тау и специфические антитела к ним |
CNA2008101081547A CN101307107A (zh) | 2001-02-02 | 2002-01-29 | tau蛋白 |
JP2002563203A JP4163955B2 (ja) | 2001-02-02 | 2002-01-29 | 構造的に異常な形のタウタンパク質およびそれに対する特異抗体 |
DK02703586.4T DK1355949T3 (da) | 2001-02-02 | 2002-01-29 | Antistoffer mod konformationelt abnorme former af tau-protein der forekommer i væv ved Alzheimers sygdom |
US10/470,928 US7446180B2 (en) | 2001-02-02 | 2002-01-29 | Conformationally abnormal forms of tau proteins and specific antibodies thereto |
AT02703586T ATE461941T1 (de) | 2001-02-02 | 2002-01-29 | Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation |
AU2002237296A AU2002237296A1 (en) | 2001-02-02 | 2002-01-29 | Conformationally abnormal forms of tau proteins and specific antibodies thereto |
PCT/EP2002/000897 WO2002062851A1 (en) | 2001-02-02 | 2002-01-29 | Conformationally abnormal forms of tau proteins and specific antibodies thereto |
CA2437453A CA2437453C (en) | 2001-02-02 | 2002-01-29 | Conformationally abnormal forms of tau proteins and specific antibodies thereto |
EP02703586A EP1355949B1 (de) | 2001-02-02 | 2002-01-29 | Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation |
DE60235746T DE60235746D1 (de) | 2001-02-02 | 2002-01-29 | Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation |
ES02703586T ES2339427T3 (es) | 2001-02-02 | 2002-01-29 | Anticuerpos contra formas conformacionalmente anormales de proteina tau presente en tejidos con enfermedad de alzheimer. |
US12/264,694 US20090123936A1 (en) | 2001-02-02 | 2008-11-04 | Conformationally abnormal forms of tau proteins and specific antibodies thereto |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0017501A AT500379B8 (de) | 2001-02-02 | 2001-02-02 | Tau-proteine |
Publications (4)
Publication Number | Publication Date |
---|---|
AT500379A2 AT500379A2 (de) | 2005-12-15 |
AT500379A3 true AT500379A3 (de) | 2009-02-15 |
AT500379B1 AT500379B1 (de) | 2009-07-15 |
AT500379B8 AT500379B8 (de) | 2009-08-15 |
Family
ID=3658236
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT0017501A AT500379B8 (de) | 2001-02-02 | 2001-02-02 | Tau-proteine |
AT02703586T ATE461941T1 (de) | 2001-02-02 | 2002-01-29 | Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02703586T ATE461941T1 (de) | 2001-02-02 | 2002-01-29 | Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation |
Country Status (12)
Country | Link |
---|---|
US (2) | US7446180B2 (de) |
EP (1) | EP1355949B1 (de) |
JP (1) | JP4163955B2 (de) |
CN (2) | CN101307107A (de) |
AT (2) | AT500379B8 (de) |
AU (1) | AU2002237296A1 (de) |
CA (1) | CA2437453C (de) |
DE (1) | DE60235746D1 (de) |
DK (1) | DK1355949T3 (de) |
ES (1) | ES2339427T3 (de) |
RU (1) | RU2299889C2 (de) |
WO (1) | WO2002062851A1 (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
DK1521831T3 (da) * | 2002-07-12 | 2008-06-30 | Axon Neuroscience | Transgent dyr der udtrykker trunkeret alzheimers tauprotein |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
AU2006319358B2 (en) | 2005-11-30 | 2012-01-19 | AbbVie Deutschland GmbH & Co. KG | Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
KR101439828B1 (ko) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
ES2321996B1 (es) * | 2006-01-26 | 2010-03-05 | Consejo Superior Investig. Cientificas | Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias. |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
WO2009143556A1 (en) * | 2008-05-30 | 2009-12-03 | The University Of Sydney | TREATMENTS FOR EXCITOTOXICITY AND Aß-MEDIATED TOXICITY AND AGE-ASSOCIATED NEURONAL DYSFUNCTION |
CA3120504A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
JP6124591B2 (ja) * | 2009-08-28 | 2017-05-10 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | タウオリゴマーに結合する抗体 |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
ITRM20100320A1 (it) | 2010-06-11 | 2011-12-11 | Consiglio Nazionale Ricerche | Metodo per la diagnostica e il trattamento delle taupatie |
EP3533803B1 (de) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antikörper |
JP2014503178A (ja) | 2010-10-11 | 2014-02-13 | バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー | ヒト抗タウ抗体 |
CA2817973C (en) | 2010-10-15 | 2019-06-25 | The Board Of Regents Of The University Of Texas System | Antibodies that bind amyloid oligomers |
US20120244174A1 (en) | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
US9506051B2 (en) * | 2011-05-20 | 2016-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
SG10201912964PA (en) | 2011-09-19 | 2020-02-27 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
EP2764022B9 (de) | 2011-10-07 | 2017-02-22 | AC Immune S.A. | Phosphospezifischer antikörper zur tau-erkennung |
CN104781278B (zh) | 2012-07-03 | 2018-06-12 | 华盛顿大学 | 针对tau的抗体 |
MX359817B (es) | 2012-08-16 | 2018-10-11 | Ipierian Inc | Anticuerpos que se enlazan a tau. |
US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
EA035932B1 (ru) | 2012-12-21 | 2020-09-02 | Байоджен Ма Инк. | Человеческие анти-тау антитела |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
AU2014248515B2 (en) | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
MX2015012872A (es) * | 2013-03-15 | 2016-02-03 | Ac Immune Sa | Anticuerpos anti-tau y metodos de uso. |
PL3083680T3 (pl) | 2013-12-20 | 2020-06-29 | F. Hoffmann-La Roche Ag | Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania |
NZ630610A (en) | 2014-02-14 | 2019-05-31 | Ipierian Inc | Tau peptides, anti-tau antibodies, and methods of use thereof |
AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
US10132818B2 (en) | 2014-07-08 | 2018-11-20 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
AR103713A1 (es) | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
CN107849124B (zh) | 2015-06-05 | 2021-09-24 | 基因泰克公司 | 抗tau抗体及使用方法 |
EP3313877B1 (de) | 2015-06-24 | 2020-06-03 | H. Hoffnabb-La Roche Ag | Humanisierte anti-tau(ps422)-antikörper und verfahren zur verwendung |
US10287343B2 (en) * | 2015-07-06 | 2019-05-14 | Ucb Biopharma Sprl | Tau-binding antibodies |
WO2017027685A2 (en) | 2015-08-13 | 2017-02-16 | New York University | Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
ES2933491T3 (es) | 2016-05-02 | 2023-02-09 | Prothena Biosciences Ltd | Inmunoterapia tau |
KR102471787B1 (ko) | 2016-05-02 | 2022-11-29 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
MY197836A (en) * | 2016-07-12 | 2023-07-20 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
WO2018031361A2 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination therapy |
AU2017373884A1 (en) | 2016-12-07 | 2019-05-30 | Ac Immune Sa | Anti-tau antibodies and methods of their use |
CR20230163A (es) | 2016-12-07 | 2023-07-06 | Genentech Inc | ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271) |
CA3061516A1 (en) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
CN107686839B (zh) * | 2017-09-25 | 2020-12-04 | 安徽朵能生物科技有限公司 | 微管结合蛋白cript、其治疗性突变体及其应用 |
JP2021530552A (ja) | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | 併用療法 |
WO2020180819A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
CA3135170A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
WO2022144406A1 (en) | 2020-12-29 | 2022-07-07 | Neurimmune Ag | Human anti-tau antibodies |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733734A (en) * | 1991-08-14 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments |
JPH06239899A (ja) | 1993-02-12 | 1994-08-30 | Teijin Ltd | ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法 |
AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
US20020164657A1 (en) * | 2001-02-23 | 2002-11-07 | Sharma Satish K. | Assays for assessing A beta-Tau aggregation |
-
2001
- 2001-02-02 AT AT0017501A patent/AT500379B8/de not_active IP Right Cessation
-
2002
- 2002-01-29 DE DE60235746T patent/DE60235746D1/de not_active Expired - Lifetime
- 2002-01-29 JP JP2002563203A patent/JP4163955B2/ja not_active Expired - Lifetime
- 2002-01-29 WO PCT/EP2002/000897 patent/WO2002062851A1/en active Application Filing
- 2002-01-29 ES ES02703586T patent/ES2339427T3/es not_active Expired - Lifetime
- 2002-01-29 CA CA2437453A patent/CA2437453C/en not_active Expired - Lifetime
- 2002-01-29 AU AU2002237296A patent/AU2002237296A1/en not_active Abandoned
- 2002-01-29 AT AT02703586T patent/ATE461941T1/de active
- 2002-01-29 CN CNA2008101081547A patent/CN101307107A/zh active Pending
- 2002-01-29 EP EP02703586A patent/EP1355949B1/de not_active Expired - Lifetime
- 2002-01-29 CN CNB028053133A patent/CN100503638C/zh not_active Expired - Lifetime
- 2002-01-29 DK DK02703586.4T patent/DK1355949T3/da active
- 2002-01-29 RU RU2003126594/13A patent/RU2299889C2/ru active
- 2002-01-29 US US10/470,928 patent/US7446180B2/en not_active Expired - Lifetime
-
2008
- 2008-11-04 US US12/264,694 patent/US20090123936A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002062851A1 (en) | 2002-08-15 |
US20090123936A1 (en) | 2009-05-14 |
AT500379B1 (de) | 2009-07-15 |
US20040082763A1 (en) | 2004-04-29 |
CN100503638C (zh) | 2009-06-24 |
CN101307107A (zh) | 2008-11-19 |
AT500379A2 (de) | 2005-12-15 |
ATE461941T1 (de) | 2010-04-15 |
AT500379B8 (de) | 2009-08-15 |
AU2002237296A1 (en) | 2002-08-19 |
RU2299889C2 (ru) | 2007-05-27 |
JP2004532817A (ja) | 2004-10-28 |
EP1355949A1 (de) | 2003-10-29 |
DE60235746D1 (de) | 2010-05-06 |
US7446180B2 (en) | 2008-11-04 |
DK1355949T3 (da) | 2010-05-25 |
CA2437453C (en) | 2013-06-11 |
EP1355949B1 (de) | 2010-03-24 |
WO2002062851A8 (en) | 2002-09-12 |
CN1492879A (zh) | 2004-04-28 |
JP4163955B2 (ja) | 2008-10-08 |
ES2339427T3 (es) | 2010-05-20 |
RU2003126594A (ru) | 2005-03-10 |
CA2437453A1 (en) | 2002-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AT500379B1 (de) | Tau-proteine | |
EA200700083A1 (ru) | Антитела, направленные против бета-амилоидного пептида, и способы их применения | |
ATE376559T1 (de) | Methoden der verhinderung und behandlung der alzheimer'schen krankheit | |
EP2147928A3 (de) | Auf Peptiden basierte Immunisierungstherapie zur Behandlung von Atherosklerose und Entwicklung von Peptid-basierten Assays zur Bestimmung von Immunreaktionen gegen oxidiertes Lipoprotein geringer Dichte | |
WO2002046222A3 (en) | Compositions and methods for diagnosing alzheimer's disease | |
ATE283289T1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
WO2005018424A3 (en) | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits | |
DK1355919T3 (da) | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf | |
DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
EA200101250A1 (ru) | Предупреждение и терапия амилоидогенного заболевания | |
HUP0302589A2 (hu) | A béta-amiloid peptidet felismerő humanizált ellenanyagok | |
EP2305286A3 (de) | Behandlung von Alzheimerkrankheit | |
DK2380583T3 (da) | Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser | |
EA200400134A1 (ru) | Терапевтический агент | |
PT723552E (pt) | Oligopeptidos derivados de fragmentos de proteina reactiva c | |
DE602006019582D1 (de) | Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen | |
AU2001232275A1 (en) | Novel collagen-like protein clac, precursor thereof and genes encoding the same | |
ATE396203T1 (de) | Auf peptiden basierende immunisierungstherapie zur behandlung von atheriosclerose | |
WO2001002429A3 (en) | Angiopoietin-6 and uses thereof | |
WO2002046769A3 (en) | A monoclonal antibody-based diagnostic assay for gamma fibrinogen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Change of the owner |
Owner name: AXON NEUROSCIENCE SE, CY Effective date: 20191118 |
|
MK07 | Expiry |
Effective date: 20210202 |